For reference: vomiting · nine · a GLP-1 receptor agonist.
I want a method I can write down and repeat, not a rule of thumb.
I would rather over-engineer this than discover a problem later, within reason.
So: what is the actual procedure, and which steps matter as opposed to being ritual?
Week 9 is day 63: on a four-week ladder that is week 1 of dose step 3, and — at the seven-day half-life this class runs on — 9 half-lives in. Steady state is about five half-lives, so day 35 is where the concentration stops climbing on its own. Day 63 is 4 weeks past it, which means the level is no longer the variable. That distinction is most of the question: at week 1 of a step, an effect that is still accumulating is indistinguishable from one that is not resolving unless you know which side of day 35 you are on. Vomiting is the rarer and more informative of the pair. It follows the same escalation weeks as nausea, so one arriving well away from a step is pointing at something other than the ladder. Dose decisions are made under supervision, and nothing here is medical advice.
Answer first: vomiting is less common than nausea, is more strongly dose-related, and matters chiefly because of what it does to fluid and electrolyte balance.
Trial incidence for vomiting runs at roughly a third to a half of the nausea rate depending on agent and dose, and it is more concentrated in the escalation phase than nausea is.
In practice, oral rehydration solutions work by glucose-coupled sodium co-transport, which continues to function when secretion is deranged. That is why the glucose-to-sodium ratio matters and a high-sugar sports drink is not equivalent.
Oral rehydration solution composition is standardised by the World Health Organization and rests on glucose-coupled sodium transport.
The caveat is that persistent vomiting is a clinical situation and this is not the place to manage one.
Small frequent sips of an oral rehydration solution, not large volumes of water.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsRehydration with an oral rehydration solution is more effective than water and is not the same as a sports drink.
Fluid lost in vomit carries sodium at roughly 60 millimoles per litre and potassium at rather less, so replacing it with plain water alone dilutes plasma sodium rather than restoring balance.
It helps to be literal here: warning signs that convert this from a nuisance to a clinical problem: inability to keep fluids down for more than a few hours, reduced urine output, dizziness on standing, confusion, or severe abdominal pain.
The renal risk here is volume, not toxicity. That is the mechanism to watch.
The honest answer is that a day of it is unpleasant and that several days of it needs help.
Repeated vomiting is the mechanism behind most reported acute kidney injury in this class. The renal event is a volume event, not a direct toxicity.
More usefully, a practical home formulation is about six level teaspoons of sugar and half a level teaspoon of salt in one litre of water, taken in small frequent sips rather than in volumes that provoke another episode.
Volume depletion as the mechanism for acute creatinine rise is basic renal physiology and explains the pattern of renal reports in this class.
Anti-emetics interact with other medication and are a prescriber decision.
Do not escalate the dose while this is happening.
Anti-emetics are a clinical decision and not a self-management step.
Dental enamel erosion from repeated vomiting is a real if unglamorous consequence; rinsing with water rather than brushing immediately is the standard advice.
Nothing here is medical advice.
Rinse rather than brush after an episode. Enamel is not replaceable.
edited 12 Aug 2025 by esther_vandeVelde — updated for the 2026 guidance change
The relevant risk chain is vomiting to volume depletion to reduced renal perfusion to a rising creatinine, which is how most acute renal events in this class occur.
An episode of vomiting several days after a dose, with no escalation and no other explanation, is not the typical pattern and deserves attention rather than tolerance.
Vomiting rates in the trial programmes are reported separately from nausea and are consistently lower and more dose-dependent.
Research-use material is not approved for human use, and an unverified dose is an unquantifiable variable in any of this.
If fluids will not stay down for several hours, that is the threshold. Get help.
edited 27 Jun 2025 by Dr_Lena_Ostrowska — reworded for clarity after a comment
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.